Venture Capital



Most ventures active in the field of the red life sciences require lots of money, time and resources before they can start selling their product and make some profit. Subsidies may provide the very initial funding, while banks are only prepared to step in once products are actually being sold and a positive cash flow is obtained. Enter venture capital to fund the stretch in between subsidies and the banks.

In my talk I will try and explain how venture capitalists work. What do we look for, how do we interact with our companies, how do we make our money? More specifically I will zoom in on our organization, Thuja Capital. I will give various examples and hope for an interactive hour during which you will get a good idea of how your future company will be able to win the venture capitalists' heart & mind.

Michel Briejer

Managing Partner, Thuja Capital
Dr. Michel Briejer (1965) joined Thuja Capital in early 2008. He has gained broad hands-on as well as strategic experience in a variety of senior management positions both in the international pharmaceutical and biotech industry (e.g. Janssen Pharmaceutical (Belgium), Astellas Pharma and Crucell). Moreover, he worked as a consultant for a number of small pharmaceutical and biotech start-up companies in The Netherlands.

Michel strengthens the Thuja team with a wealth of drug development know-how, ranging from chemically synthesized drugs to complex proteins produced with biotechnological methods. Moreover, having been in charge of various drug development programs as a project leader, he understands the complexity of drug development and project management, and has built a large network of specialists.

Michel holds a BSc degree in Chemical Technology (Delft University), a MSc degree in Pharmacy (Utrecht University) and a PhD in Pharmacology (Wageningen University), as well as a post-doctoral degree in Pharmaceutical Medicine (European Center for Pharmaceutical Sciences, Basel). Michel authored over 25 peer reviewed scientific papers and book chapters on pharmacology and drug development.

Michel was a director on the supervisory board of Bioceros, Cavadis and DCPrime, and currently serves on the boards of Fabpulous, NightBalance, Cristal Delivery, Mellon Medical, NutriLeads and MILabs.


Jumpstart your career

Join BioBusiness Summer School to jumpstart your career in Life Sciences by gaining knowledge of business aspects such as product development, IPR, finance and business models. The next edition of the summer school will be organised from 25-29 June 2018 in Amsterdam, Leiden and Utrecht, the Netherlands. Register now!

Why participate

The BioBusiness Summer School is a programme tailored to bridge the gap. By immersing yourself in the business aspects of Life Sciences during this programme, you will learn the basic knowledge of BioBusiness, gain insight in the world of Life Sciences companies, meet leading business leaders and increase your international network.

Employers meet talent

Is your organisation interested in early-career talents in Life Sciences? BioBusiness Summer School can get you in touch with business oriented PhDs, postdocs or Master students. More info can be found here.